Pharmaceuticals, Biotechnology and Life Sciences
Biocartis and Genomic Health have entered a deal to develop an IVD version of the Oncotype DX Breast Recurrence Score…
Biocartis Group got clearance for the Idylla Respiratory (IFV-RSV) Panel from the US Food and Drug Administration (FDA). Idylla Respiratory…
Biocartis Group NV has published two study abstracts about the performance of its new set of biomarkers for microsatellite instability…
Biocartis Group said on Wednesday that on the day before, July 11, 2017 the US FDA published a final list of devices that it has exempted from 510(k) premarket notification requirements in accordance with the US 21st Century Cures Act (signed into US law 13 December 2016).
Biocartis has today strenghten its collaboration with two companies; J&J’s Jansen and Amgen, as it has submitted 510(k) its diagnostics…
Biocartis has CE-marked its solid biopsy Idylla NRAS-BRAF Mutation Test. On Thursday, Biocartis said that, together with the CE-marked Idylla…
Biocartis Group NV, a Belgian innovative molecular diagnostics company has published a comparative study organised by AstraZeneca where 12 different KRAS mutation detecting technologies, including Next-Generation Sequencing (NGS) and quantitative Polymerase Chain Reaction (PCR), were compared for the detection of KRAS mutations in lung cancer, using blinded samples.